Man Group PLC Stoke Therapeutics, Inc. Transaction History

Man Group PLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$3.37 - $5.4 $330,863 - $530,166	-98,179 Reduced 86.47%	15,361 $80,000
Q3 2023 Nov 14, 2023	BUY	$3.78 - $11.99 $64,207 - $203,662	16,986 Added 17.59%	113,540 $447,000
Q2 2023 Aug 14, 2023	SELL	$7.93 - $13.82 $65,303 - $113,807	-8,235 Reduced 7.86%	96,554 $1.03 Million
Q1 2023 May 15, 2023	BUY	$7.65 - $10.38 $801,635 - $1.09 Million	104,789 New	104,789 $872,000
Q3 2022 Nov 14, 2022	BUY	$12.56 - $22.53 $790,513 - $1.42 Million	62,939 New	62,939 $808,000

123

57.6M

9.3K

35.2K

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $474M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.